<DOC>
	<DOCNO>NCT01414933</DOCNO>
	<brief_summary>High sensitivity target agent observed patient whose tumor cell present genetic/genomic deregulation target ( Kit mutation , ERBB2 amplification , EGFR mutation ) together addiction give target . More recently , activation `` alternative pathway '' ( Kras mutation , PI3K mutation ) report common resistance mechanism single agent tyrosine kinase inhibitor ( trastuzumab , cetuximab ) . From data emerge hypothesis identification deregulate pathway new molecular tool could allow propose tailor targeted regimen . Based concept , number phase I/II trial enrich population patient present specific molecular alteration . High throughput technology ( array CGH , sequence , gene expression array ) identify deregulate gene . In addition , technology determine whether genomic alteration single ( expect efficacy single agent ) multiple ( rationale combination ) . In pilot study include 135 patient , recently perform combination array CGH hot spot mutation array order drive patient phase I/II clinical trial . This study lead conclusion high throughput technology i. feasible ( 80 % ) robust , ii . identify `` targetable '' genomic alteration around 40 % sample . In present study , investigator perform high throughput technology drive 400 metastatic breast cancer patient specific phase I/II trial .</brief_summary>
	<brief_title>High Throughput Technologies Drive Breast Cancer Patients Specific Phase I/II Trials Targeted Agents</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Men Women histologically diagnose breast cancer Metastatic relapse stage IV breast cancer diagnosis Metastases amenable biopsy Age &lt; 70 year old PS 0/1 No restriction regard number previous chemotherapy endocrine therapy Age &lt; 18 Life expectancy &lt; 3 month Symptomatic progress brain metastasis Progressive patient time biopsy LVEF &lt; 50 % ( MUGA ultrasonography ) Inadequate bone marrow reserve organ function demonstrate follow laboratory value : Absolute neutrophil count &lt; 1.5 x 109/L Platelet count &lt; 100 x 109/L Haemoglobin &lt; 90 g/L ASAT/ALAT &gt; 2.5 time upper limit normal ( ULN ) demonstrable liver metastasis &gt; 5 time ULN presence liver metastases Total bilirubin &gt; 1.5 time ULN Creatinine &gt; 1.5 time ULN Corrected calcium &gt; ULN Phosphate &gt; ULN Abnormal blood coagulation contraindicates biopsy Patients deprive liberty place authority tutor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>